MCKESSON CORP
MCKAPI behind this page
MCK Q2 2026 request
Playground key active
/api/financials?ticker=MCK&year=2026&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | 103,150 | 93,651 | +10.1% |
Show Business Segments breakouts |
|||
| Medical-Surgical Solutions · Operating Segments | 2,947 | 2,946 | 0.0% |
| North American Pharmaceutical · Operating Segments | 86,481 | 80,018 | +8.1% |
| Oncology & Multispecialty · Operating Segments | 12,044 | 9,157 | +31.5% |
| Prescription Technology Solutions · Operating Segments | 1,376 | 1,265 | +8.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 302 | 265 | +14.0% |
| Cost of Revenue | -99,608 | -90,403 | -10.2% |
| Gross Profit | 3,542 | 3,248 | +9.1% |
| Selling, General & Administrative | -2,074 | -2,503 | +17.1% |
| Gain Loss Related To Litigation Settlement | 2 | 4 | -50.0% |
| Restructuring Costs And Asset Impairment Charges | -63 | -171 | +63.2% |
| Operating Expenses | -2,135 | -2,670 | +20.0% |
| Operating Income | 1,407 | 578 | +143.4% |
| Non-Operating Income (Expense) | 62 | 34 | +82.4% |
| Interest Expense | -74 | -78 | +5.1% |
| Income Loss Including Portion Attributable To Noncontrolling Interest | 1,395 | 534 | +161.2% |
| Income Tax Expense (Benefit) | -232 | -247 | +6.1% |
| Net Income | 1,163 | 287 | +305.2% |
| Net Income Loss Attributable To Noncontrolling Interest | -53 | -46 | -15.2% |
Show Ownership breakouts |
|||
| ClarusONE Sourcing Services, Vantage Oncology, SCRI Oncology, and Prism Vision | -48 | -46 | -4.3% |
| Net Income | 1,110 | 241 | +360.6% |
| EPS (Diluted) | 8.92 | 1.87 | +377.0% |
| EPS (Basic) | 8.95 | 1.88 | +376.1% |
| Wtd Avg Shares (Diluted) | 124.4 | 129.3 | -3.8% |
| Wtd Avg Shares (Basic) | 124 | 128.7 | -3.7% |
| Income Before Taxes | 1,395 | 534 | +161.2% |
| Comprehensive Income | 1,100 | 264 | +316.7% |
| Depreciation And Amortization | 188 | 163 | +15.3% |
Show Business Segments breakouts |
|||
| Medical-Surgical Solutions · Operating Segments | 23 | 22 | +4.5% |
| North American Pharmaceutical · Operating Segments | 32 | 43 | -25.6% |
| Oncology & Multispecialty · Operating Segments | 71 | 37 | +91.9% |
| Prescription Technology Solutions · Operating Segments | 20 | 22 | -9.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 41 | 34 | +20.6% |
| Material Reconciling Items | 1 | 5 | -80.0% |
Balance Sheet
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 4,004 | 2,509 | +59.6% |
| Receivables Net Current | 28,286 | 25,270 | +11.9% |
| Inventory | 26,134 | 24,176 | +8.1% |
| Prepaid Expenses & Other Current Assets | 1,463 | 751 | +94.8% |
| Total Current Assets | 59,887 | 53,341 | +12.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,627 | 2,361 | +11.3% |
| Operating Lease Right-of-Use Assets | 1,991 | 1,495 | +33.2% |
| Goodwill | 11,283 | — | — |
Show Business Segments breakouts |
|||
| Medical-Surgical Solutions · Operating Segments | 2,507 | — | — |
| North American Pharmaceutical · Operating Segments | 2,781 | — | — |
| Oncology & Multispecialty · Operating Segments | 3,929 | — | — |
| Prescription Technology Solutions · Operating Segments | 2,066 | — | — |
| Intangible Assets | 4,220 | 1,573 | +168.3% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 820 | 876 | -6.4% |
| Other Intangible Assets | 98 | 8 | +1125.0% |
| Provider Networks | 352 | — | — |
| Service Agreements | 2,503 | 422 | +493.1% |
| Technology Based Intangible Assets | 161 | 151 | +6.6% |
| Trademarks And Trade Names | 286 | 116 | +146.6% |
| Other Non-Current Assets | 4,152 | 3,572 | +16.2% |
| Total Assets | 84,160 | 72,429 | +16.2% |
| Current Liabilities | |||
| Accounts Payable | 60,938 | 53,317 | +14.3% |
| Long Term Debt And Capital Lease Obligations Current | 1,747 | — | — |
| Operating Lease Liability Current | 278 | 243 | +14.4% |
| Accrued Liabilities | 5,068 | — | — |
| Total Current Liabilities | 68,031 | 58,771 | +15.8% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 1,086 | 1,048 | +3.6% |
| Operating Lease Liabilities | 1,756 | 1,232 | +42.5% |
| Litigation Reserve Noncurrent | 5,103 | 5,617 | -9.2% |
| Other Non-Current Liabilities | 2,751 | 2,712 | +1.4% |
| Long-Term Debt | 7,758 | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Fair Value Measurements Recurring | 7,758 | — | — |
Show Debt Instrument breakouts |
|||
| 0.90% Notes due December 3, 2025 · Loans Payable | 500 | — | — |
| 1.30% Notes due August 15, 2026 · Loans Payable | 500 | — | — |
| 1.50% Euro Notes due November 17, 2025 · Loans Payable | 704 | — | — |
| 1.63% Euro Notes due October 30, 2026 · Loans Payable | 587 | — | — |
| 3.13% Sterling Notes due February 17, 2029 · Loans Payable | 605 | — | — |
| 3.95% Notes due February 16, 2028 · Loans Payable | 343 | — | — |
| 4.25% Notes due September 15, 2029 · Loans Payable | 500 | — | — |
| 4.65% Notes due May 30, 2030 · Loans Payable | 650 | — | — |
| 4.75% Notes due May 30, 2029 · Loans Payable | 196 | — | — |
| 4.88% Notes due March 15, 2044 · Loans Payable | 255 | — | — |
| 4.90% Notes due July 15, 2028 · Loans Payable | 400 | — | — |
| 4.95% Notes due May 30, 2032 · Loans Payable | 650 | — | — |
| 5.10% Notes due July 15, 2033 · Loans Payable | 597 | — | — |
| 5.25% Notes due May 30, 2035 · Loans Payable | 698 | — | — |
| 6.00% Notes due March 1, 2041 · Loans Payable | 217 | — | — |
| 7.65% Debentures due March 1, 2027 · Loans Payable | 150 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Lease and other obligations | 206 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 6,011 | 5,691 | +5.6% |
| Redeemable Noncontrolling Interest Equity Common Carrying Amount | 777 | — | — |
Show Equity Components breakouts |
|||
| Redeemable Noncontrolling Interests | 777 | — | — |
| Stockholders' Equity | |||
| Common Stock | 3 | 3 | 0.0% |
| Additional Paid-In Capital | 8,499 | 8,221 | +3.4% |
| Retained Earnings | 19,622 | 15,959 | +23.0% |
| Accumulated Other Comprehensive Income | -908 | -890 | -2.0% |
| Treasury Stock Common Value | -28,955 | -26,310 | -10.1% |
| Total Stockholders' Equity | -1,739 | -3,017 | +42.4% |
| Minority Interest | 384 | 375 | +2.4% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1,355 | -2,642 | +48.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Net Gain Loss Including Portion Attributable To Noncontrolling Interest | 13 | -19 | +168.4% |
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -873 | -843 | -3.6% |
| Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest | 5 | -6 | +183.3% |
| Accumulated Other Comprehensive Income | -908 | -890 | -2.0% |
| Additional Paid In Capital | 8,499 | 8,221 | +3.4% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -908 | -890 | -2.0% |
| Common Stock | 3 | 3 | 0.0% |
| Noncontrolling Interest | 384 | 375 | +2.4% |
| Retained Earnings | 19,622 | 15,959 | +23.0% |
| Treasury Stock Common | -28,955 | -26,310 | -10.1% |
| Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax | -53 | -22 | -140.9% |
| Total Liabilities & Equity | 84,160 | 72,429 | +16.2% |
Cash Flow Statement
| Metric | YTD Q2 2026 | YTD Q2 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 124 | 124 | 0.0% |
| Adjustment For Amortization | 221 | 208 | +6.2% |
| Other Asset Impairment Charges | 4 | 76 | -94.7% |
| Increase Decrease In Deferred Income Taxes | -41 | 125 | -132.8% |
| Inventory L I F O Reserve Period Charge | -18 | -4 | -350.0% |
| Operating Lease Expense | 140 | 113 | +23.9% |
| Gain Loss On Sale Of Other Assets | -85 | -89 | +4.5% |
| Provision For Doubtful Accounts | 232 | -169 | +237.3% |
Show Business Segments breakouts |
|||
| North American Pharmaceutical | 189 | -203 | +193.1% |
| Other Non-Cash Items | 169 | 174 | -2.9% |
| Increase Decrease In Receivables | -2,296 | -3,499 | +34.4% |
| Change in Inventory | -3,199 | -3,310 | +3.4% |
| Change in Accounts Payable | 5,170 | 6,221 | -16.9% |
| Increase Decrease In Operating Lease Liability | -152 | -196 | +22.4% |
| Increase Decrease In Accrued Taxes Payable | 121 | -145 | +183.4% |
| Increase Decrease In Litigation Reserve | -657 | -386 | -70.2% |
| Increase Decrease In Other Operating Capital Net | -225 | -408 | +44.9% |
| Net Cash from Operations | 1,502 | 720 | +108.6% |
| Investing Activities | |||
| Capital Expenditures | -217 | -242 | +10.3% |
| Payments To Acquire Software | -168 | -143 | -17.5% |
| Payments To Acquire Businesses Net Of Cash Acquired | -3,389 | -1 | -338800.0% |
| Proceeds From Divestiture Of Businesses And Interests In Affiliates | 133 | 93 | +43.0% |
| Other Investing Activities | 53 | -80 | +166.2% |
| Net Cash from Investing | -3,588 | -373 | -861.9% |
| Financing Activities | |||
| Proceeds From Short Term Debt | 2,275 | 6,876 | -66.9% |
| Repayments Of Short Term Debt | -2,275 | -6,876 | +66.9% |
| Proceeds From Issuance Of Long Term Debt | 1,990 | 498 | +299.6% |
| Repayments Of Long Term Debt | -2 | -501 | +99.6% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 50 | 54 | -7.4% |
| Share Repurchases | -1,399 | -2,019 | +30.7% |
| Payments Of Dividends Common Stock | -179 | -162 | -10.5% |
| Proceeds From Payments For Other Financing Activities | -245 | -278 | +11.9% |
| Net Cash from Financing | 215 | -2,408 | +108.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 24 | 1 | +2300.0% |
| Net Change in Cash | -1,847 | -2,074 | +10.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4,109 | 2,511 | +63.6% |
| Restricted Cash Current | -105 | -2 | -5150.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.